Voyager Logo.png
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
September 25, 2023 07:00 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Logo.png
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2023 16:01 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Logo.png
Voyager Therapeutics to Participate in Upcoming Investor Conferences
August 30, 2023 07:00 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Logo.png
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2023 16:01 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Logo.png
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
August 07, 2023 08:00 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Logo.png
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
August 03, 2023 07:00 ET | Voyager Therapeutics, Inc.
- Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio - - Executed license agreement with Sangamo for prion disease treatment - -...
Voyager Logo.png
Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference
August 02, 2023 07:00 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Logo.png
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
July 27, 2023 07:00 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Logo.png
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023 16:01 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Logo.png
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
July 10, 2023 08:00 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...